The role of chemotherapy in biliary tract carcinoma

HPB

Volumn 10, Issue 3, 2008, Pages 164-167

  Verslype, C ^a   Prenen, H ^a   Van Cutsem, E ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LAPATINIB; MITOMYCIN C; OXALIPLATIN; PLATINUM DERIVATIVE;

BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BILIARY TRACT SURGERY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LIVER TRANSPLANTATION; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREOPERATIVE CARE; RECURRENT CANCER; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 47649128913     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1080/13651820802029427     Document Type: Review

References (26)

1. de Groen, PC, Gores, GJ, LaRusso, NF, Gunderson, LL and Nagorney, DM. (1999) Biliary tract cancers. N Engl J Med, 341, pp. 1368-1378.
2. Jarnagin, WR, Fong, Y., DeMatteo, RP, Gonen, M., Burke, EC Bodniewicz, BSJ et al. (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg, 234, pp. 507-517.
3. Bakkevold, KE, Arnesjø, B., Dahl, O. and Kambestad, B. (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-Results of a controlled, prospective, randomised multicentre study. Eur J Cancer, 29, pp. 698-703.
4. Smeenk, HG, van Eijck, CH, Hop, WC, Erdmann, J., Tran, KC Debois, M. et al. (2007) Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: Long-term results of EORTC trial 40891. Ann Surg, 246, pp. 734-740.
5. Glimelius, B., Hoffman, K., Sjoden, PO, Jacobsson, G., Sellstrom, H. Enander, LK et al. (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol, 7, pp. 593-600.
6. Eckel, F. and Schmid, RM. (2007) Chemotherapy in advanced biliary tract carcinoma: A pooled analysis of clinical trials. Br J Cancer, 96, pp. 896-902.
7. Chen, JS, Jan, YY and Lin, YC. (1998) Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs, 9, pp. 393-397.
8. Choi, CW, Choi, IK and Seo, JH. (2000) Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol, 23, pp. 425-428.
9. Kubicka, S., Rudolph, KL, Tietze, MK, Lorenz, M. and Manns, M. (2001) Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology, 48, pp. 783-789.
10. Gallardo, JO, Rubio, B., Fodor, M., Orlandi, L., Yanez, M. Camargo, C. et al. (2001) A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol, 12, pp. 1403-1406.
11. Park, JS, Oh, SY, Kim, SH, Kwon, HC, Kim, JS Jin-Kim, H. et al. (2005) Single-agent gemcitabine in the treatment of advanced biliary tract cancers: A phase II study. Japan J Clin Oncol, 35, pp. 68-73.
12. Ueno, H., Okusaka, T., Ikeda, M., Takezako, Y. and Morizane, C. (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer., 91, pp. 1769-1774.
13. Andre, T., Tournigand, C., Rosmorduc, O., Provent, S., Maindrault-Goebel, F. Avenin, D. et al. (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: A GERCOR study. Ann Oncol, 15, pp. 1339-1343.
14. Kim, ST, Park, JO, Lee, J., Lee, KT, Lee, JK Choi, SH et al. (2006) A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer, 106, pp. 1339-1346.
15. Riechelmann, RP, Townsley, CA, Chin, SN, Pond, GR and Knox, JJ. (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer, 110, pp. 1307-1312.
16. Nehls, O., Oettle, H., Hartmann, JT, Hofheinz, RD, Hass, HG Horger, MS et al. (2008) Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: A prospective multicentre phase II trial. Br J Cancer, 98, pp. 309-315.
17. Taieb, J., Mitry, E. Boige, V. et al. (2002) Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol, 13, pp. 1192-1196.
18. Kim, YJ, Im, SA, Kim, HG, Oh, SY, Lee, KW Choi, IS et al. (2008) A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol, 19, pp. 99-103.
19. Kornek, GV, Schuell, B., Laengle, F., Gruenberger, T., Penz, M. Karall, K. et al. (2004) Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: A randomised phase II trial. Ann Oncol, 15, pp. 478-483.
20. Ducreux, M., Van Cutsem, E., Van Laethem, JL, Gress, TM, Jeziorski, K. Rougier, P. et al. (2005) A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: Results of the 40955 EORTC trial. Eur J Cancer, 41, pp. 398-403.
21. Rao, S., Cunningham, D., Hawkins, RE, Hill, ME, Smith, D. Daniel, F. et al. (2005) Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer, 92, pp. 1650-1654.
22. Yoon, JH, Higuchi, H., Werneburg, NW, Kaufmann, SH and Gores, GJ. (2002) Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology, 122, pp. 985-993.
23. Philip, PA, Mahoney, MR, Allmer, C., Thomas, J., Pitot, HC Kim, G. et al. (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol, 24, pp. 3069-3074.
24. Ramanathan, RK, Belani, CP, Singh, DA, Tanaka, M., Lenz, HJ Yen, Y. et al. (2006) Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her/2-neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California consortium (CCC-P) trial. Proc Am Soc Clin Oncol, 24, p. 18S.
25. Paule, B., Herelle, MO, Rage, E., Ducreux, M., Adam, R. Guettier, C. et al. (2007) Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology, 72, pp. 105-110.
26. Rea, DJ, Heimbach, JK, Rosen, CB, Haddock, MG, Alberts, SR Kremers, WK et al. (2005) Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg, 242, pp. 451-458.